(0.07%) 5 311.59 points
(0.02%) 39 813 points
(0.02%) 16 798 points
(-0.74%) $79.21
(-2.84%) $2.67
(-0.53%) $2 425.60
(-1.07%) $32.08
(-0.08%) $1 062.80
(0.08%) $0.921
(-0.27%) $10.67
(-0.02%) $0.787
(-0.42%) $90.29
1.81% $ 0.630
Live Chart Being Loaded With Signals
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States...
Stats | |
---|---|
Volumen de hoy | 20 141.00 |
Volumen promedio | 3.85M |
Capitalización de mercado | 11.01M |
EPS | $0 ( 2024-05-09 ) |
Próxima fecha de ganancias | ( $-0.0900 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.210 |
ATR14 | $0.00600 (0.95%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Cittadine Andrew | Sell | 8 952 | Restricted Stock Units |
2024-03-31 | Cittadine Andrew | Buy | 8 952 | Common Stock |
2024-03-31 | Cittadine Andrew | Sell | 3 098 | Common Stock |
2024-03-31 | Tsuchimoto Kim R | Sell | 9 956 | Restricted Stock Units |
2024-03-31 | Tsuchimoto Kim R | Buy | 9 956 | Common Stock |
INSIDER POWER |
---|
36.17 |
Last 100 transactions |
Buy: 1 127 208 | Sell: 341 037 |
Volumen Correlación
Monopar Therapeutics Inc Correlación
10 Correlaciones Más Negativas | |
---|---|
BLKB | -0.804 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Monopar Therapeutics Inc Correlación - Moneda/Commodity
Monopar Therapeutics Inc Finanzas
Annual | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-0.610 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-0.610 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-0.830 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.730 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico